Ian Miller, MD: Adapting AAV Gene Therapy for SCN1A-Positive Epilepsy

Video

The medical director of the Comprehensive Epilepsy Clinic at Nicklaus Children’s Hospital discusses his early stage gene therapy trial for Dravet syndrome.

“Before the natural history of the patient has declared itself, you really don't know whether they will have Dravet syndrome or a severity thats somewhere else on the GEFS+ spectrum.”

Loss of function mutations in the SCN1A gene often result in various seizure disorders, most commonly Dravet syndrome, in which nearly 90% of patients have a mutation on the gene.

Given the success of gene therapies in other neurologic disorders, such as spinal muscular atrophy, researchers believe that a modified approach may also hold promise for SCN1A-positive epilepsies. At the 2019 American Epilepsy Society Annual Meeting, Ian Miller, MD, medical director of the Comprehensive Epilepsy Clinic at Nicklaus Children’s Hospital, and colleagues, presented a novel approach to adeno-associated viral vector-based gene therapy for SCN1A-positive epilepsy.

Miller detailed how one of the challenges with current gene therapy approaches is that the viral vectors can only accommodate small genes, not large, complex ones like SCN1A. Instead, Miller and colleagues approach targets vector expression to GABAergic interneurons and upregulates endogenous SCN1A expression. Results from a mouse model study of Dravet syndrome showed that the engineered viral vector dramatically reduced hyperthermic and spontaneous seizures.

To learn more about the new approach, Miller sat down with NeurologyLive at AES 2019.

For more coverage of AES 2019, click here.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.